PHARMACY PRACTICE MODULE
PHARMACY PRACTICE-III
Third year
Lecturers: A. Serracino Inglott, L.M. Azzopardi
Lectur
e No.
Lecture Title
1
12/10/09
Pharmacists’ care plans
and Pharmacist
Prescribing
2
12/10/09
Research
methodology-III
3
19/10/09
Cardiovascular
disorders
4
19/10/09
Schizophrenia
5
26/10/09
Hypertension
6
26/10/09
Mood disorders
PHR-3107
8 credits
Lecture Schedule
Description
Pharmacists are in a position to fill the
pharmaceutical care gap that occurs in
the practical setting whereby there is
lack of optimal amount of therapeutic
planning. A general introduction to the
planning phase and the development
of disease specific drug treatment
protocols is presented so as to serve
as a basis for disease-oriented
discussions in these credits. An
introduction to the concept of
pharmacist prescribing is presented.
Observational methods
Surveys
Questionnaire construction
Data preparation and analysis
The pharmacists interventions during
the diagnostic and treatment phases
are aimed to help patients achieve the
desired outcomes of therapy. Clinical
assessment and parameters that
should be monitored in cardiovascular
disease are discussed.
Schizophrenia, which is a chronic,
debilitating illness where the goal of
treatment is to control psychotic
symptoms, is discussed. A
comparative approach to antipyschotic
medications is adopted.
The management of hypertension,
which is considered a major risk factor
for cardiovascular and cerebrovascular
disease, is discussed. Review of
causes of lack of responsiveness to
antihypertensive therapy and of
considerations for individualizing drug
therapy due to co-existing disease
states.
Depression is an affective disorder
where patient presents with varying
degrees of low mood. Drug treatment
is the mainstay of treatment in
moderate to severe depression but for
treatment to be successful it should be
supported by non-pharmacologic
strategies. Management of acute and
major depression is discussed.
Lecturer
ASI
LA
ASI
LA
ASI
LA
7
9/11/09
Ischaemic heart
disease
8
9/11/09
Anxiety disorders
9
23/11/09
Congestive heart failure
10
23/11/09
Sleep disorders
11
4/1/10
Hyperlipidaemia
12
4/1/10
Eating disorders
13
11/1/10
Thrombosis
14
11/1/10
Antihistamine drugs
and allergic rhinitis
15
18/1/10
Skin Disorders
16
18/1/10
Genito-urinary
disorders
17
8/2/10
Dispensing of
adrenergic and
cholinergic drugs
18
8/2/10
Menopause and
Hormone replacement
therapy (HRT)
A condition where there is impairment
in the supply of oxygenated blood to
cardiac tissue. Treatment of risk
factors is discussed and patient
education necessary is emphasised.
Diagnostic criteria to differentiate
generalized anxiety disorder from the
normal response to stress are
reviewed. The use of antidepressants
and benzodiazepines in the treatment
of anxiety disorder is discussed.
The goal of therapy in cardiac failure is
to control symptoms of heart failure.
Medications used to treat heart failure
with special reference to common
management mistakes are discussed.
Difficulties in falling asleep or staying
asleep or lack of refreshment from
sleep are common complaints. The
rational use of hypnotic drugs and the
counselling that should be undertaken
on proper sleep hygiene are
discussed.
When hyperlipidaemia is uncontrolled
by diet and lifestyle modifications
alone, drug therapy is considered.
Review of drug therapy, risk of side
effects and medication expenses and
dietary compliance.
Eating disorders are discussed with
special reference to anorexia nervosa
and bulimia.
Management of thrombosis with
particular reference to patient
education.
Comparative approach to
antihistamine drugs used for allergic
rhinitis and the common cold.
Management of skin allergies, acne
and psoriasis is reviewed.
Use of drugs for urinary retention,
urinary incontinence and urological
pain is reviewed.
Review of adrenergic drugs,
cholinergic and cholinergic blocking
drugs; their indications, side effects to
be expected and patient counselling.
Menopause is associated with
problems resulting from the ensuing
loss of oestrogen in the body. HRT is
discussed considering advantages
offered, pharmaceutical dosage forms
available and patient education.
ASI
LA
ASI
LA
ASI
LA
ASI
LA
ASI
LA
ASI
LA
Dementia and
Alzheimer’s disease
Treatment options in particular
innovative disease-specific therapy are
discussed. Measurement of patients’
quality of life and of the decline in
cognitive symptoms will be presented
as pharmacotherapy outcome
measurements.
Occurrence of menstrual cycle
disorders and treatment options is
discussed. Oral contraception with
emphasis on patient counselling and
on the various preparations available is
discussed.
Medication errors are a cause of
concern and require establishment of
controlled drug distribution systems
and comprehensive pharmacy
services. Methods and issues
considered in addressing this issue are
discussed.
The concept of evaluation of
professional services provided by the
pharmacist is presented. Methods
adopted to evaluate quality of
professional services provided are
reviewed. Audit exercises and
validation tools are discussed.
The management of viral infectious
diseases will be discussed taking as
an example Hepatitis infection. Various
treatment modalities are presented.
The treatment regimens used in the
management of HIV infected patients
are discussed. Pharmacist
interventions in this speciality are
presented.
19
15/2/10
20
15/2/10
Menstrual cycle
disorders and
contraception
22/2/10
Risks and use of
medicines
22/2/10
Quality standards in
pharmacy practice
1/3/10
Hepatitis infection
1/3/10
HIV infection
15/3/10
2226/3/10
12/4 21/5
Discussion
Pharmacy Symposium
ASI/LA
ASI/LA
Practicals
ASI/LA
21
22
23
24
ASI
LA
ASI
LA
ASI
LA